Cellectar to Participate at Upcoming Institutional Investor Conferences

Rhea-AI Summary

Cellectar Biosciences (NASDAQ: CLRB) announced participation in upcoming conferences for 1x1 meetings. The H.C. Wainwright Global Life Sciences Conference will take place on March 9-10, 2021, and the Roth Capital Partners 33rd Annual Conference from March 15-17, 2021. Interested parties can schedule meetings through provided links. Cellectar focuses on developing cancer-targeting drugs using its Phospholipid Drug Conjugate™ (PDC) platform, including its lead product CLR 131, currently in pivotal trials for various cancers.

FLORHAM PARK, N.J., March 05, 2021 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today announced that the company will be available for 1x1 meetings at the following upcoming conferences:

H.C. Wainwright Global Life Sciences Conference
Date:	March 9-10, 2021
Time:	Available for 1x1 meetings
	To schedule, click on the link HERE
Roth Capital Partners 33rd Annual Conference
Date:	March 15-17, 2021
Time:	Available for 1x1 meetings
	To schedule, click on the link HERE

The company’s presentation is available for on-demand viewing in the link HERE.

About Cellectar Biosciences, Inc.
Cellectar Biosciences is focused on the discovery, development and commercialization of drugs for the treatment of cancer. The company is developing proprietary drugs independently and through research and development collaborations. The company’s core objective is to leverage its proprietary Phospholipid Drug Conjugate™ (PDC) delivery platform to develop PDCs that specifically target cancer cells, delivering improved efficacy and better safety as a result of fewer off-target effects. The company’s PDC platform possesses the potential for the discovery and development of the next-generation of cancer-targeting treatments, and it plans to develop PDCs independently and through research and development collaborations.

The company’s product pipeline includes CLR 131, a small-molecule PDC designed to provide targeted delivery of iodine-131 (radioisotope) directly to cancer cells, while limiting exposure to healthy cells unlike many traditional on-market treatment options. CLR 131, is currently being evaluated in the CLOVER-WaM Phase 2 pivotal study in patients with relapsed/refractory (r/r) Waldenstrom’s macroglobulinemia, a Phase 2b study in r/r multiple myeloma patients, the CLOVER-2 Phase 1 study for a variety of pediatric cancers, one preclinical PDC chemotherapeutic program (CLR 1900) and multiple partnered PDC assets.

For more information, please visit www.cellectar.com or join the conversation by liking and following us on the company’s social media channels: Twitter, LinkedIn, and Facebook.

Contacts

Investors:
Monique Kosse
Managing Director
LifeSci Advisors
212-915-3820
monique@lifesciadvisors.com

FAQ

What conferences will Cellectar Biosciences be attending in March 2021?

Cellectar Biosciences will be attending the H.C. Wainwright Global Life Sciences Conference on March 9-10 and the Roth Capital Partners 33rd Annual Conference on March 15-17.

How can I schedule a meeting with Cellectar Biosciences during the conferences?

Meetings can be scheduled by clicking the links provided in the press release for each conference.

What is CLR 131 and its significance for Cellectar Biosciences?

CLR 131 is a small-molecule Phospholipid Drug Conjugate designed for targeted delivery of iodine-131 to cancer cells, currently in pivotal studies for relapsed/refractory cancers.

What platform does Cellectar Biosciences use for drug delivery?

Cellectar uses its proprietary Phospholipid Drug Conjugate™ (PDC) delivery platform to target cancer cells effectively.

What types of cancer is Cellectar targeting with its drugs?

Cellectar is developing treatments for various cancers, including Waldenstrom’s macroglobulinemia and multiple myeloma.